Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · IEX Real-Time Price · USD
1.860
-0.130 (-6.53%)
At close: Apr 19, 2024, 4:00 PM
1.950
+0.090 (4.84%)
After-hours: Apr 19, 2024, 7:41 PM EDT
Eledon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ELDN stock have an average target of 10.67, with a low estimate of 9.00 and a high estimate of 13. The average target predicts an increase of 473.66% from the current stock price of 1.86.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ELDN stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +598.92% | Mar 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +598.92% | Nov 13, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $25 → $13 | Strong Buy | Maintains | $25 → $13 | +598.92% | Oct 24, 2023 |
| Noble Capital Markets | Noble Capital Markets | Buy Initiates $10 | Buy | Initiates | $10 | +437.63% | Sep 27, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $9 | Buy | Reiterates | $9 | +383.87% | Aug 22, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.48
from -1.64
EPS Next Year
-0.80
from -1.48
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | n/a | 18.3M |
| Avg | n/a | n/a | n/a | n/a | 5.9M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.13 | -0.82 | -0.98 | -1.11 | -1.07 |
| Avg | -1.48 | -0.80 | -0.95 | -1.08 | -1.04 |
| Low | -1.78 | -0.76 | -0.91 | -1.04 | -1.00 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.